-+ 0.00%
-+ 0.00%
-+ 0.00%

Caribou Biosciences posts CB-011 CaMMouflage phase 1 follow-up presentation on relapsed/refractory multiple myeloma

PUBT·06/11/2026 12:17:56
Listen to the news
Caribou Biosciences posts CB-011 CaMMouflage phase 1 follow-up presentation on relapsed/refractory multiple myeloma
  • Caribou Biosciences published updated long-term dose-escalation results from the Phase 1 CaMMouflage trial of CB-011 in relapsed or refractory multiple myeloma.
  • BCMA-naïve patients treated at the 450 million-cell recommended expansion dose showed 92% overall response rate, 83% complete response or better.
  • MRD negativity reached 91% in evaluable patients; 50% remained in complete response or better at 15 months.
  • Safety update reported no graft-versus-host disease; grade 3 or higher infections occurred in 17% at selected lymphodepletion.
  • Enrollment continues in dose expansion at the 450 million-cell dose in BCMA-naïve cohorts, BCMA-exposed cohorts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.